This paper outlines a study protocol for a randomized clinical trial designed to optimize electroacupuncture (EA) treatment for Bell’s palsy. By comparing two distinct electrical waveforms across different levels of nerve damage severity, the researchers aim to move EA from a traditional practice toward a standardized, evidence-based medical intervention.
TL;DR
This study protocol details a randomized, three-center clinical trial comparing the efficacy of low-frequency continuous vs. intermittent electroacupuncture waveforms for Bell’s palsy. By stratifying 120 patients based on objective nerve damage (ENoG values), the trial seeks to identify optimal stimulation parameters for different stages of facial paralysis severity.
What Problem Does This Paper Address?
Bell’s palsy (BP) is the leading cause of acute peripheral facial paralysis. While many patients recover spontaneously, a significant minority suffer from permanent functional and aesthetic impairments. Electroacupuncture (EA)—which combines traditional needling with consistent electrical pulses—is widely used to promote nerve regeneration and muscle excitability.
However, EA is currently a "black box" of parameters. Practitioners use various frequencies, intensities, and waveforms with little consensus on which is most effective. Specifically, there is a lack of data on whether the waveform (the pattern of the electrical pulse) should be adjusted based on the severity of the nerve damage. This study addresses the lack of a standardized EA protocol, which currently hinders both clinical efficacy and the ability to conduct high-quality meta-analyses.
Methods
The trial is a pilot randomized, two-arm, three-center study conducted in Hangzhou, China.
- Stratification: Participants are divided into two severity groups based on Electroneurography (ENoG) values: those with $\ge$ 20% nerve function and those with < 20% (indicating more severe damage).
- Intervention: Within each severity group, patients are randomized 1:1 to receive one of two EA waveforms:
- Low-frequency continuous waveform: 2Hz stimulation for 20 minutes.
- Intermittent waveform: 40Hz stimulation (repeated on-off cycles) for 20 minutes.
- Dosing: Participants receive 12 sessions over 4 weeks (3 times per week).
- Blinding: A "two-acupuncturist" model is used. One performs the needling, while another operates the EA device. This allows for the blinding of participants, outcome assessors, and data analysts, even though the device operator cannot be blinded.
Datasets
As this is a study protocol, it does not contain a results dataset. Instead, it defines the recruitment target: 120 participants (60 per severity group) recruited from the outpatient units of three hospitals:
- The First Affiliated Hospital of Zhejiang Chinese Medical University.
- The Third Affiliated Hospital of Zhejiang Chinese Medical University.
- Hangzhou First People’s Hospital.
Key Insights and Ideas
- Physiological Specificity of Waveforms: The authors hypothesize that different waveforms trigger different biological pathways. Previous research suggests 2Hz continuous waves may be superior for nerve regeneration, while 30–50Hz intermittent waves may better prevent muscle atrophy and enhance excitability.
- Objective Severity Markers: Rather than relying solely on visual scales, the study uses ENoG to measure the Compound Muscle Action Potential (CMAP). This provides a quantitative, biological baseline of nerve degeneration.
- FNGS 2.0 vs. House-Brackmann: The study adopts the Facial Nerve Grading System 2.0 as its primary outcome. This is a more modern, granular, and reliable metric than the traditional House-Brackmann scale, reducing inter-rater variability.
Key Results
Note: Results are not yet available as the trial is ongoing (expected completion December 2025).
The primary outcome will be the change from baseline in the FNGS 2.0 score at week 4. Secondary outcomes include changes in the Sunnybrook grading scale and ENoG amplitude. The authors expect the findings to provide a preliminary basis for determining which waveform is most beneficial for specific degrees of facial nerve damage.
Limitations and Future Work
- No Sham Control: This pilot trial compares two active treatments. The authors acknowledge that future larger-scale studies will need a sham EA or conventional acupuncture group to establish absolute efficacy.
- Short Duration: A 4-week treatment window may be insufficient to capture the full recovery trajectory of patients in the "severe" (< 20% ENoG) group.
- Geographic Concentration: All three clinical centers are located in the same city, which may limit the generalizability of the findings to broader populations.
- Future Directions: The authors suggest that future research should explore longer follow-up periods and investigate other common frequencies (like 20Hz) to further refine the "optimal" EA prescription.
Summary updated